What the trials showed
Two 24-week randomized trials in premenopausal women with hypoactive sexual desire disorder found that bremelanotide improved desire scores and reduced related distress compared with placebo; the changes were modest. The approved label describes the population, how it is used and its limits.
Side effects
In the approved product’s trials, about four in ten women had nausea, usually after the first doses. Flushing, injection-site reactions and headache were also common. Blood pressure rises and heart rate falls briefly after a dose. Darkening of patches of skin has been reported, especially with frequent use.
What about men?
Bremelanotide is not FDA-approved for men. Early studies looked at erectile dysfunction, but low desire and erectile function are different problems with different treatments. A clinician should first work out which concern you have.
Compounded PT-141
A compounded bremelanotide vial is prepared by a pharmacy for an individual prescription. It is not Vyleesi and does not share its FDA approval or its evidence base for other uses.